InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis
April 21, 2026
Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient, […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 20, 2026
By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 17, 2026
Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]
Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
April 16, 2026
Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus […]
Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook
April 15, 2026
Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A recent analysis from Zacks Small-Cap Research provides that perspective for Soligenix (NASDAQ: SNGX), offering a detailed review of the company’s pipeline, upcoming […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
April 14, 2026
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. “Soligenix exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
April 2, 2026
Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse […]
Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publication
April 1, 2026
The publication of clinical research in peer-reviewed journals remains a critical milestone in drug development, offering independent validation and broader visibility for emerging therapies. Soligenix (NASDAQ: SNGX) recently reached such a milestone with the publication of a clinical summary of its HyBryte(TM) therapy, reinforcing the importance of scientific transparency as the company advances treatments for […]
Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition
March 31, 2026
A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development that highlights both the potential of […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
March 31, 2026
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim analysis expected in Q2 2026 and top-line results anticipated in the second half of the year. The company also noted regulatory momentum with orphan drug designation for […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
March 26, 2026
Soligenix (NASDAQ: SNGX) announced the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease, following a positive recommendation from the European Medicines Agency and supportive Phase 2a data demonstrating biological efficacy and safety. The designation provides up to 10 years of market exclusivity in the European Union and adds to existing FDA orphan and […]
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
March 24, 2026
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer
March 23, 2026
Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
March 23, 2026
Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), […]
Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
March 20, 2026
Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewed Journal Publication
March 19, 2026
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs, highlighting the therapy’s safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phase 3 HyBryte Progress And Key Inflection Points
March 19, 2026
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast episode where CEO Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte(TM) for cutaneous T-cell lymphoma, noting strong blinded aggregate response rates above initial assumptions and outlining potential outcomes including early study completion or continued enrollment, while […]
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
March 19, 2026
AUSTIN, Texas, March 19, 2026 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews […]
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline
March 18, 2026
Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and commercializing therapies and vaccines for rare diseases […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease
March 10, 2026
Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions […]
Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development
March 9, 2026
For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX), a late-stage […]
Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
March 5, 2026
Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix (NASDAQ: SNGX) exemplifies this strategy through its use of synthetic hypericin […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease
February 26, 2026
Soligenix (NASDAQ: SNGX) announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation of dusquetide, the active ingredient in SGX945, for the treatment of Behçet Disease, following review of recently published Phase 2a data demonstrating biological efficacy and safety. The recommendation now advances to the European Commission for ratification. The company noted that orphan designation […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit
February 24, 2026
Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options
February 12, 2026
Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line data from the Phase 3 FLASH2 trial of HyBryte™ in early-stage cutaneous T-cell lymphoma expected in the second half of 2026, with an interim analysis approaching in the second quarter and […]
Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology
February 10, 2026
From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin […]
InvestorNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach
February 6, 2026
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. “Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that […]
Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer
February 2, 2026
Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new burdens. Soligenix (NASDAQ: SNGX) […]
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
January 30, 2026
As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and diagnostic delays can persist for years, prolonging suffering and […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM)
January 29, 2026
Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX) efforts to develop therapies aimed at addressing critical gaps in rare disease treatment, including CTCL. The publication reads, “Within a challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic […]
InvestorNewsBreaks – RiVax(R) Positions Soligenix Inc. (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts
January 23, 2026
Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against ricin exposure. These efforts position the company at the center of biodefense preparedness as public awareness of ricin’s lethality grows. “In a counter-terrorism operation in India, […]
Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease
January 16, 2026
Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry particular importance. Soligenix (NASDAQ: SNGX) is reporting results from a phase 2a proof of […]
Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL
January 14, 2026
Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema or psoriasis, leading to frequent misdiagnosis and delayed treatment. These diagnostic delays can allow the disease to progress silently for years, increasing patient suffering and […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)
January 9, 2026
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study […]
Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study
December 22, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational […]
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
December 19, 2025
A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease
December 18, 2025
Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
December 17, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies
December 10, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in a new NetworkNewsAudio APR titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now.” The feature underscores the growing impact of chronic and rare conditions on older adults, with more than 30 million Americans affected […]
Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone
December 8, 2025
When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant. Soligenix (NASDAQ: SNGX), a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need, recently […]